Lenalidomide revenue decline sharper than expected
Lenalidomide sales expected to drop significantly after Q2 FY26; magnitude depends on pricing and competitor behavior.
high · management_commentary
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Semaglutide launch delays due to IP or regulatory hurdles
Canadian launch contingent on patent litigation outcome in India and FDA approval; any delay could push revenue to later quarters.
high · analyst_questionUS generic price erosion persists
Base US business faces ongoing price erosion; management expects flat to single-digit growth but uncertainty remains.
medium · data_observationSG&A costs may remain elevated
SG&A at 30% of sales in Q1; management targets 28-29% for full year, but NRT and nutraceutical investments could keep it higher.
medium · analyst_question